SB-435495

structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Booker, M L: 1 article (10/2001)

1.	Atherosclerosis 10/01/2001 - "GlaxoSmithKline is investigating a series of substituted pyrimidin-4-ones, including SB-435495, as reversible inhibitors of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) for the potential treatment of atherosclerosis [339220], [422380]. "

1.	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)